ReviewClinical reviews in allergy & immunology2013
Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity.
Review in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Type I interferons in bacterial diseases: myeloid cells at the crossroads of protection and pathology.Frontiers in immunology · 2025Review
- The extracellular heparan sulfatase SULF2 limits myeloid IFNβ signaling and Th17 responses in inflammatory arthritis.Cellular and molecular life sciences : CMLS · 2024Article
- SHP2: its association and roles in systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Interferon therapy and its association with depressive disorders - A review.Frontiers in immunology · 2023Review
- Peripheral Blood Th1/Th17 Immune Cell Shift is Associated with Disease Activity and Severity of AQP4 Antibody Sero-Positive Neuromyelitis Optica Spectrum Disorder.Neuropsychiatric disease and treatment · 2023Article
- Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis.Frontiers in immunology · 2023Article
- STAT1 signaling protects self-reactive T cells from control by innate cells during neuroinflammation.JCI insight · 2022Article
- Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells.Nature immunology · 2022Article
- Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.Frontiers in neurology · 2022Review
- Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.Biomedicines · 2021Article
- G-protein-coupled receptor P2Y10 facilitates chemokine-induced CD4 T cell migration through autocrine/paracrine mediators.Nature communications · 2021Observational
- Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells.Research square · 2021Article
- Neuroinflammation Associated With Inborn Errors of Immunity.Frontiers in immunology · 2021Review
- The IL-27/IL-27R axis is altered in CD4Clinical & translational immunology · 2021Article
- Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells.bioRxiv : the preprint server for biology · 2020Article
- Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.Clinical reviews in allergy & immunology · 2020Review
- Contribution of STAT1 to innate and adaptive immunity during type I interferon-mediated lethal virus infection.PLoS pathogens · 2020Article
- Relationship Between T-Cell Exosomes and Cellular Subsets in SLE According to Type I IFN-Signaling.Frontiers in medicine · 2020Article
- Neuromyelitis optica spectrum disorders: still evolving and broadening.Current opinion in neurology · 2019Review
- LFA-1 Controls Th1 and Th17 Motility Behavior in the Inflamed Central Nervous System.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In relapsing remitting multiple sclerosis (RRMS), type I interferon (IFN) is considered immuno-modulatory, and recombinant forms of IFN-β are the most prescribed treatment for this disease. However, within the RRMS population, 30-50% of MS patients are nonresponsive to this treatment, and it consistently worsens neuromyelitis optica (NMO), a disease once considered to be a form of RRMS. In contrast to RRMS, type I IFNs have been shown to have properties that drive the inflammatory pathologies in many other autoimmune diseases. These diseases include Sjögren's syndrome, system lupus erythematosus (SLE), neuromyelitis optica (NMO), rheumatoid arthritis (RA) and psoriasis. Historically, autoimmune diseases were thought to be driven by a TH1 response to auto-antigens. However, since the discovery of the TH17 in experimental autoimmune encephalomyelitis (EAE), it is now generally thought that TH17 plays an important role in MS and all other autoimmune diseases. In this article, we will discuss recent clinical and basic research advances in the field of autoimmunity and argue that IFN-β and other type I IFNs are immuno-modulatory in diseases driven predominantly by TH1 but in contrast are inflammatory in diseases that have a predominant Th17 response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.